Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease-Reference-Cited by-同舟云学术

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

Published:2020-08-15 Issue:16 Volume:59 Page:1939-1945
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Fujita Tetsuo¹,Kuroki Tsuguko¹,Hayama Nami¹,Shiraishi Yuka¹,Amano Hiroyuki¹,Nakamura Makoto¹,Hirano Satoshi²,Tabeta Hiroshi¹,Nakamura Sukeyuki¹

Affiliation:

1. Department of Respirology, Funabashi Municipal Medical Center, Japan

2. Department of Medical Oncology, Funabashi Municipal Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/59/16/59_4552-20/_pdf

Reference26 articles.

1. 1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.

2. 2. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37: 537-546, 2019.

3. 3. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188: 733-748, 2013.

4. 4. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 172: 488-493, 2005.

5. 5. Ozawa Y, Akahori D, Koda K, et al. Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer. Cancer Chemother Pharmacol 77: 1031-1038, 2016.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis;Respiratory Investigation;2024-05

2. Are Immune Checkpoint Inhibitors Safe and Effective in Lung Cancer Patients with Pre-Existing Interstitial Lung Disease?;Immunotherapy;2024-03-21

3. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review;Frontiers in Immunology;2023-01-10

4. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases;Chest;2022-06

5. Pembrolizumab induced pneumonitis;Radiopaedia.org;2021-10-06